Clinical trial identifies promising target for liver disease treatments

An international clinical trial involving Birmingham Professor Phil Newsome identified a promising target for patients with non-alcoholic steatohepatitis (NASH), as reported in a paper published yesterday (Nov. 6) in Nature Communications. The research team demonstrated that an oral inhibitor of amine oxidase copper-containing 3 (AOC3)—a protein involved in liver inflammation that can lead to fibrosis, cirrhosis and liver cancer—successfully suppressed this protein and reduced liver injury.